- 1 Prediction of the risk for diabetic neuropathy among diabetes mellitus patients at
- 2 selected referral hospitals, in Amhara regional state Northwest Ethiopia, January,
- 3 2005- December 2021; Development and validation of risk prediction model
- 4 Negalgn Byadgie Gelaw^{*1*} Achenef Asmamaw Muche² Adugnaw Zeleke Alem³ Nebiyu
- 5 Bekele Gebi⁴ Yazachew Moges Chekol⁵ Tigabu Kidie Tesfie⁶ Tsion Mulat Tebeje⁷
- ⁶ ¹Department of public health, Mizan- Aman College of health sciences, Mizan- Aman,
- 7 Ethiopia
- 8 ²Department of Epidemiology and biostatics, College of medicine and health sciences,
- 9 University of Gondar, Gondar, Ethiopia

³Department of Epidemiology and biostatics, College of medicine and health sciences,

- 11 University of Gondar, Gondar, Ethiopia
- ⁴Department of internal medicine, School of Medicine, University of Gondar comprehensive
- 13 specialized hospital, Gondar, Ethiopia
- ⁵Department of Health Information Technology, Mizan Aman College of health sciences,
- 15 Mizan-Aman, Ethiopia
- ⁶ Department of Public Health, College of Health Sciences, Debre Markos University, Debre
- 17 Markos, Ethiopia
- ⁷ Unit of Epidemiology and biostatistics, School of public health, college of medicine and
- 19 health sciences, Dilla University, Dilla, Ethiopia
- 20 Corresponding Author *1* (<u>negalgnbyadgie21@gmail.com</u>)
- 21 Emails:
- 22 NBG; <u>negalgnbyadgie21@gmail.com</u>
- 23 AAM; <u>ashua2014@gmail.com</u>
- 24 AZA: <u>aduzeleke2201@gmail.com</u>
- 25 NBG; <u>dawabekele@gmail.com</u>

- 26 YMC; <u>vazachewmoges@gmail.com</u>
- 27 TKT; tigabukidie@gmail.com
- 28 TMT; yemarina12@gmail.com
- 29

30 Abstract

Background:-Diabetic neuropathy is the most common complication in both Type-1 and 31 32 Type-2 DM patients with more than one half of all patients developing nerve dysfunction in 33 their lifetime. Although, risk prediction model was developed for diabetic neuropathy in 34 developed countries, It is not applicable in clinical practice, due to poor data, methodological problems, inappropriately analyzed and reported. To date, no risk prediction model 35 36 developed for diabetic neuropathy among DM in Ethiopia. Therefore, this study aimed prediction the risk of diabetic neuropathy among DM patients, used for guiding in clinical 37 decision making for clinicians 38

39

Objective:- Prediction of the risk for diabetic neuropathy among diabetes mellitus patients,
in selected referral hospitals, Amhara regional state, northwest Ethiopia,2022

42 Methods:- A retrospective follow up study was conducted with a total of 808 DM patients 43 were enrolled from January 1,2005 to December 30,2021 at two selected referral hospitals in Amhara regional state. Multi-stage sampling techniques were used and the data was collected 44 by checklist from medical records by Kobo collect and exported to STATA version-17 for 45 analysis. Lasso method were used to select predictors and entered to multivariable logistic 46 47 regression with P-value<0.05 was used for nomogram development. Model performance was assessed by AUC and calibration plot. Internal validation was done through bootstrapping 48 49 method and decision curve analysis was performed to evaluate net benefit of model

50

Results:-The incidence proportion of diabetic neuropathy among DM patients was 21.29 %(95% CI; 18.59, 24.25).In multivariable logistic regression glycemic control, other comorbidities, physical activity, hypertension, alcohol drinking, type of treatment, white blood cells and red blood cells count were statistically significant. Nomogram was developed, has discriminating power AUC; 73.2 %(95% CI; 69.0%, 77.3%) and calibration test (P-value = 0.45). It was internally validated by bootstrapping method with discrimination performance 71.7(95% CI; 67.2 %, 75.9%).It had less optimism coefficient (0.015).To make

nomogram accessible, mobile based tool were developed. In machine learning, classification
and regression tree has discriminating performance of 70.2 %(95 % CI; 65.8%, 74.6%). The
model had high net benefit at different threshold probabilities in both nomogram and
classification and regression tree.

62

63 **Conclusion:-** The developed nomogram and decision tree, has good level of accuracy and 64 well calibration, easily individualized prediction of diabetic neuropathy. Both models had 65 added net benefit in clinical practice and to be clinically applicable mobile based tool were 66 developed.

67 Key-words:-Prediction, Diabetes mellitus, Diabetic neuropathy, Ethiopia

68 Background

Diabetes mellitus is metabolic disorder disease characterized by increasing blood glucose level in the body resulting from either defect insulin secretion, insulin action, or both(1) with around 90% have type 2 DM and 10% have type-1 DM(2).According to IDF, the global prevalence of diabetes mellitus in 20-79 year olds at 2021 was estimated to be 536.6 million people, rising to 783.2 million in 2045(3).

Globally, around 3 million deaths annually is due to DM and 49.7% living with diabetes undiagnosed (4).It is one of the most common problem in the world has faced both in developed and developing countries (5). In Africa, by 2019, around 19 million adult populations were estimated to have diabetes and it is expected that by 2045 it will be around 47 million and similarly in Ethiopia, an estimated 1,699,400 adults were living with diabetes mellitus(6).

The chronic hyperglycemia of diabetes mellitus had long-term damage, dysfunction, and failure of different organs such as nerves, eyes, kidneys(7). Diabetic neuropathy defined as presence of symptoms and signs of peripheral nerve dysfunction in people with diabetes mellitus after exclusion of other causes(8). The mechanism of nerve dysfunctions was through metabolic process by hyperglycemia due to oxidative stress, directly affecting nerve fibers (9). It is the most common complication of both type-1 and type-2 DM with more than one half of all patients developing nerve dysfunction in their lifetime (10).

The Burdon of diabetic neuropathy common in industrialized countries ranges from in china, 33.1%(11) to 40.3% among patients with type-1 diabetes mellitus and 42.2% with type-2 diabetes mellitus in Germany (12). Evidence from previous study documented shows that in Latin American and Caribbean countries, the incidence of diabetic neuropathy was 29.2% (13) and in Sri Lankan 28.8%(14).

In Africa, according to a systematic review and meta-analysis done, the overall pooled
prevalence of diabetic neuropathy was 46% (15). In south Africa 30.3% (16) ,in Ghana 8.1%
(17), in Northern Africa, incidence ranges from 21.9% to 60% (18).

In Ethiopia, the prevalence of diabetic neuropathy ranges from 16.63% at university of
Gondar comprehensive specialized referral hospital to 52.2% at Bahir-Dar city (19), at TikurAnbesa and St. Paul's specialized university hospital was 48.2% with 53.6% in type 2 and
33.3% in type 1 diabetes mellitus patients(20).

99 As part of NCD prevention and treatment strategies, diabetic neuropathy and related 100 complications are getting attention at the national and international levels(21).Guidelines are 101 recommending that by multidisciplinary team approach can treating and preventing diabetic

neuropathy. WHO and other professional society guideline are also recommended that
 strengthening of the surveillance & management of diabetic neuropathy was important to
 reduce the incidence and its consequence(22).

Despite different strategies and initiatives implemented to reduce the Burdon of diabetic neuropathy, up to one third of patients with diabetes have neuropathic pain(23) which often leads to sleep disturbance, poor quality of life, depression, and unemployment. Both acute and chronic diabetic neuropathies had occur in DM patients (24) that results diabetic foot disease, including ulceration and non-traumatic amputations that might be due to lack of screening tool that can be used to identify diabetic patients who is at risk of diabetic neuropathy.

Although, risk prediction model for diabetic neuropathy among DM patients in developed countries was developed, it is not applicable in clinical practice due to poor data, methodological problems, inappropriately analyzed and poorly reported(25). Delay and lack of detection of the complication was mostly resulted from patients being asymptomatic during the early stage of the disease(26). So that a simple and accurate risk prediction tool to identify those at high risk of patents develop to diabetic neuropathy had great value.

Early identification of high risk DM patients using simple screening tool, avoids late diagnosis of diabetic neuropathy that reduces huge economic costs and serious complications (27). Thus, a method used to provide information about their level of risk was needed to take timely intervention measures to prevent occurrence of diabetic neuropathy.

Many epidemiological studies on diabetic neuropathy, including cross-sectional studies are carried out around the world to explore the risk factors associated with diabetic neuropathy (12, 28) but level of risk to develop diabetic neuropathy for DM patients was unknown. Hence studies suggest that patient specific model like individual patients risk prediction model is useful to alleviate the problem.

Risk prediction models have been used to predict the probability of risk of diseases used in 127 medicine and public health to guide clinical decision-making(29). However, risk prediction 128 model for diabetic neuropathy among DM patients have not been developed in Ethiopia. 129 There was variability in the clinical diagnosis of diabetic neuropathy in different setting 130 (30). Thus, this prediction model considers prognostic factors that have been generally 131 monitored in clinical practice and precisely measured to ensure its feasibility and accuracy 132 for clinical application. Currently an urgent change for improvement of the diagnosis and 133 134 management of diabetic neuropathy were needed(31).

135 According to a previous risk prediction model conducted to identify DM patients at risk of developing diabetic neuropathy being old age(32), sex(33), educational level (34) were 136 significant predictors with area under ROC curve of 0.957. In another study, age(35), 137 residence (3), BMI (36), educational level (34), poor diabetic control(37), type of DM(38), 138 139 duration of diabetes mellitus (39), number of hypoglycemic drugs used (40) with AUC 0.859 140 were also determinates of diabetic neuropathy. Hemoglobin level(41), presence of other micro and macro vascular complications(13), hypertension(39), type of DM (33) baseline 141 comorbidities(42), complications such as diabetic nephropathy, diabetic-retinopathy(12), 142 lipid profile(triglyceride, cholesterol)levels (43), fasting blood glucose (44, 45), HbA1c (46), 143 high level of alcohol drinking(13) physical inactive(39), eating fat containing foods(47) were 144 the most common predictors of diabetic neuropathy. 145

Although, different strategies and interventions have been made so far, to reduce the Burdon diabetic neuropathy, Overtime at least 50% of individuals with diabetes develop diabetic neuropathy(48). It is preventable through detected early the high risk patients, by providing timely intervention measures. However, identifying high risk patients for diabetic neuropathy was not performed as expected(26).

Until an advanced stage, diabetic neuropathy is asymptomatic but it can be prevented through identifying high risk patients and prompt treatment before their complication. Up to my knowledge there is no risk prediction model for diabetic neuropathy among DM patients in Ethiopia. As a result, this risk prediction models alleviate the problem by developing nomogram and decision tree, estimate disease risk, can guide healthcare providers for disease intervention and arrangement future health care needs by providing treatment.

Monitoring biomarkers and other predictors is also very essential to be aware of metabolic abnormality by providing meaningful prognostic information that can help to differentiate patients with regard complication and lead the way to change other intervention. This risk prediction model was developed by applying sound statistical methods and analysis to identify DM patients at which level of risk for the development of diabetic neuropathy (49).

Besides, the finding of this study was highly useful as a simple clinical tool to guide clinicians for decision making, aid for specific screening of high-risk patients and for their informed choice of treatment to the patients. Therefore, these studies aimed development and validation of risk prediction model for diabetic neuropathy among diabetes mellitus patients in selected referral hospitals at Amhara regional state, Ethiopia.

167

168 Methods and materials

169 Study design and area

An institution-based retrospective follow up study was conducted among patients diagnosed with diabetes mellitus from January 1, 2005 to December 30, 2021. The study area was selected referral hospitals in northwest part of Amara regional state, which includes University of Gondar Comprehensive specialized and referral hospital, Debre markos comprehensive specialized hospital, Tibebe-Gihon comprehensive specialized referral hospital, Felge-Hiwot comprehensive specialized referral hospital, and Debre tabor comprehensive specialized referral hospital.

Using lottery Method, University of Gondar comprehensive specialized referral hospital and Felege-Hiwot comprehensive specialized referral hospital was selected. University of Gondar comprehensive specialized hospital found in Gondar town, far from Addis Abeba, the capital city of Ethiopia 750 km and 200 km from Bahir-dar , the capital city of Amhara regional state. It serves for more than 7 million people in northwest Ethiopia. The hospital serves around 24,862 numbers of people are having chronic follow-up per year, and among this, 4760 were DM patients.

Felege-Hiwot Referral Hospital is found in Bahir-Dar, which is the capital city of Amhara regional state located at 565 km from Addis Ababa, Northwest Ethiopia. It serves as over 7 million people from the surrounding area. Around 21,218 people had a chronic follow-up in this hospital and among these 4200 were DM patients. The study setting was displayed below

188 **Population**

The source population was all people diagnosed with diabetes mellitus having a follow up at 189 selected referral hospitals in Amhara regional state, North West Ethiopia and all people 190 having confirmed diabetes mellitus started treatment and follow up at selected referral 191 hospitals in Amhara regional state with in follow up period were study population. A 192 diabetes mellitus patient who was enrolled from January 1, 2005 to December 30, 2021 with 193 minimum of two years follow up, at university of Gondar comprehensive specialized hospital 194 and Felege-Hiwot comprehensive specialized referral hospital were included. Diabetes 195 mellitus patients whose date of initiation was not recorded and incomplete charts, those DM 196 patients develop diabetic neuropathy at beginning, transferred in and gestational diabetes 197 mellitus was excluded 198

199 Sample size calculation and sampling technique

In risk prediction model development sample size was calculated through different
 approaches/methods either considering Minimum Mean Absolute Prediction Error (MAPE)
 to be minimum and use shrinkage factor to be minimize the issue of over fitted model.

Therefore, by applying the expected average error of predicting the outcome when the developed prediction model is going to be applied to new individuals should be considered, that is called Mean Absolute Prediction Error (MAPE) should be minimum. Sample size also can be calculated using the following formula by taking the prevalence according to a systematic review and meta-analysis study done in Ethiopia , the prevalence of diabetic neuropathy among diabetes mellitus patients was 22%(50).

209 $n = \exp\left(\frac{-0.508 + 0.259 \ln(\phi) + 0.504 \ln(p) - \ln(MAPE)}{0.544}\right)$ 210Equation 1

Here ϕ -is the proportion of diabetic neuropathy P- is the number of predictors used to predict the diabetic neuropathy and MAPE is the mean absolute prediction error of maximum 5% considered in our case.

214
$$n = \exp\left(\frac{-0.508 + 0.259 \ln(0.22) + 0.504 \ln(22) - \ln(0.05)}{0.544}\right) = 475$$

The second method is taking the issue of over fitted model in to consideration in prediction model. We have targeted less than 10% over fitted model for predicting diabetic neuropathy in DM patients. The amount of sample size required to minimize the problem of over fitting should be identified. We consider the following sample size formula.

219
$$n = \frac{P}{(S-1)\ln\left(1 - \frac{R_{CS}^2}{S}\right)}$$
.....Equation 2

220
$$R_{CS}^2 = R_{nagelkerke}^2 * max (R_{CS}^2)$$
.....Equation 2a

221 max
$$(R_{CS}^2) = 1 - \exp\left(\frac{2\ln L_{null}}{n}\right)$$
.....Equation 2b

222
$$\ln \operatorname{Lnull} = \operatorname{Eln}\left(\frac{E}{n}\right) + (n - E)\ln\left(1 - \frac{E}{n}\right)$$
.....Equation 2c

223

224
$$\ln \text{Lnull} = 22\ln\left(\frac{22}{100}\right) + (100 - 22)\ln\left(1 - \frac{22}{100}\right) = -52.7$$

225
$$\max(R_{CS}^2) = 1 - \exp(\frac{2*-52.7}{100}) = 0.65$$

226
$$R_{CS}^2 = R_{nagelkerke}^2 * max (R_{CS}^2) = 0.5*0.65 = 0.325$$

227
$$n = \frac{P}{(S-1)\ln(1-\frac{R_{CS}^2}{S})} = \frac{22}{(0.9-1)\ln(1-\frac{0.325}{0.9})} = 492$$

Here, *inLnull* is the log-likelihood of an intercept-only model; E is the total numbers of DM patients develop diabetic neuropathy, S- shrinkage factor taken as 0.9 for optimum non-over fitted model n- is the arbitrary sample size from it E occurs. Max R²CS is the maximum cox-Snell variability explained by the model δ – is the expected model optimism, $R_{nagelkerke}^2$ is also a fundamental overall measure of model fitness, it is usually considered as default of 0.5.

From the above different types of approaches for sample size calculation in risk prediction model the largest sample size is 492 and since multi stage sampling technique was used, design effect taken as equal to 1.5, Then 492*1.5=738 Finally by adding 15% contingency because of while during data extraction checklist pretesting, to check completeness and clarity of checklist, most of the patient medical record number was absent in the medical record room by taking in to consideration such missing charts, adding 10-15% contingency was recommended so, the total minimum sample size was 849.

Multi stage sampling techniques were used by first selecting the referral hospitals in North West part of Amhara regional state. Among these referral hospitals by using lottery method UOG comprehensive specialized referral hospital and Felege-Hiwot comprehensive specialized referral hospital were selected. Then, study participates were selected by first proportion allocation to each selected referral hospitals through the following proportional allocation formula.

246 $ni = \frac{n}{N} * Ni$ Where n=Total sample size N-total population ni- sample size for each hospital

Finally the study participates was selected by using computer random generated numberthrough preparing sampling frame by arranging his/her medical record number order.

A total of 8960 Type-1 and Type-2 diabetes mellitus patients were enrolled from January 1, 2005 up to December 30,2021 and had follow up at university of Gondar comprehensive specialized referral hospital and Felege Hiwot comprehensive specialized referral hospital. The flow chart of participates selection was displayed (Figure-1).

Figure 1:-Flowchart of participant selection for the development of nomogram for prediction of diabetic neuropathy among DM patients in selected referral hospitals, Amhara regional state, North West Ethiopia, 2005-2021.

256 Variables

257 Dependent variable

- 258 Diabetic neuropathy
- 259 Independent variable
- 260 Socio demographic variables: Baseline age (year), sex, residence, body mass index

261 Laboratory related variables: Mean fasting blood glucose level, Mean arterial blood

- pressure, baseline total cholesterol, baseline triglyceride level, baseline value of WBC, RBC,
- 263 platelets count, baseline hemoglobin and creatinine level
- **Diagnosis and treatment related variables**; Type of DM, duration of DM, Type of treatment for DM, hypertension, baseline other comorbidities and adherence
- 266 **Behavioral related variables;** Alcohol drinking, unhealthy diet, physical activity

267 **Operational definition**

Diabetic neuropathy; It can be either small fiber neuropathy or large fiber neuropathy. Small fiber neuropathy manifested by pain, tingling, paraesthesia and confirmed by pinprick and temperature examination. Large fiber neuropathy is manifested by numb feet and gait ataxia and confirmed by touch sensation by 10g monofilament, vibration sense by biothesiometer and ankle reflex. A patient is considered as having diabetic neuropathy if he/she is diagnosed as diabetic neuropathy on his/her medical record (51).

- 274 **Other comorbidities**; if other baseline disease (except hypertension) in DM patients were 275 present such as ischemic heart diseases, stroke, e.t.c
- 276 Mean arterial blood pressure; calculated as MABP = (SBP + (2 * DBP))/3
- 277 ➤ Normal----- 70-100 mmHg
- 279 Glycemic control: Patients was classified as per the WHO criteria into:
- 280 \blacktriangleright Good glycemic control = fasting blood glucose of 80–130 mg/dl
- 281 \blacktriangleright Poor glycemic control = fasting blood glucose of > 130 mg/dl----- (52)

282	Total cholesterol:	Total Triglyceride
283	\rightarrow Normal = <200 mg/dl	Normal= <150 mg/dl
284	➢ High >200 mg/dl(53)	High>150mg/dl(53)

285 White blood cells Red blood cells

286	➢ Normal 4,500-11,000 cells/micro liter	Normal= 4-6 million cells/ml
287	➢ Low <4,500 cells/ml	Low =<4 million cells/ml
288	➢ High >11,000 cells/ml(54)	High >6 million cells/ml(54)
289	Platelets	Body mass index:
290	Normal150,000-400,000 cells/ml	Underweight = BMI < 18.5 kg/m ²
291	Low <150,000 cells/ml	Normal weight = BMI 18.5 to 24.9 kg/m ²
292	High >400,000 cells/ml(54)	Overweight = BMI >=25 kg/m ² (55)

Data collection tools and quality control

This risk prediction model was used secondary data source, collected from June 8 to July 10, 294 2022 using the developed data extraction check lists. The reviewed records were identified 295 296 by their medical registration number. Patient intake form, follow-up card, and DM registration book were used as data sources. Socio-demographic characteristics, behavioral 297 characteristics, baseline, and follow-up clinical and laboratory data were collected from 298 patient cards. The date that patients start regular follow-up treatment until the end of the 299 300 study to the confirmation of a final event in the study period was collected. Four trained BSc nursing health professional and two public health officer supervisors were recruited for data 301 302 collection. Training on the objective of the study and how to retrieve records as per data extraction checklists were given to data collectors and supervisors one day before data 303 304 collection. As well as, random sample from data extracted was crosschecked for its consistency. The information formats were crosschecked with the source card on the spot, 305 306 and regular supervisions were done.

307 Data processing and analysis

Data was coded and entered to Kobo collect Version v2022.1.2 for clean-up and then exported to Stata version-17 for analysis. Descriptive statistics (frequency, percentage, proportion, and mean with standard deviation, median with IQR) were used to describe the clinical course of diabetic neuropathy diseases. The candidate prognostic factors were selected by using the least absolute shrinkage and selection operator (LASSO) method, by shrinking variables with very unstable estimates towards zero, it can effectively exclude some irrelevant variables and produce sparse estimations while variables with nonzero

regression coefficient was considered as most strongly associated with the response variable. Then selected variables by (LASSO) method were entered in to multivariable logistic regression and model reduction was done using log likelihood ratio test >0.15 and finally pvalue < 0.05 in model reduction were taken as statistically significant predictors and beta coefficients with 95% CI was reported. Multi-collinerity was checked by variance inflation factor where VIF > 10 indicate the presence of multi-collinearity.

321 Missing data management

Missing variable with value <50%, the missing data was handled by multiple imputation 322 through checking the type of missing data. In this risk prediction model the missing variable 323 was checked by fitting statistical test (logistic regression) found a result, the missing variable 324 was associated with the observed variables, indicates that Missing at random (MAR). The 325 percentage of missing value was done by "mdesc" package by STATA version-17 and if the 326 missing value $\geq 50\%$, were not included in our model. From 22 predictors, six of them had 327 complete data: baseline age, sex, residence, type of DM, type of treatment for DM and 328 duration. The remaining missing variables were managed by multiple imputation technique, 329 better that considers mean and variance and decreases uncertainty or bias. The missing 330 variables and its percentage value was found in (Supplementary file S-1) 331

332 Risk prediction model development

In risk prediction model development both the prognostic markers and determinates that predict the diabetic neuropathy was selected from socio-demographic factors, diagnosis and treatment related factors, laboratory related factors and behavioral related factors. The determinants factors included in the multivariable logistic regression analysis were selected based on the results of lasso regression method. The theoretical design was the incidence of diabetic neuropathy at a future time "t" is a function of prognostic determinants ascertained at one time (baseline) points before the occurrence of the diabetic neuropathy ("t0")

- 340 The occurrence relation was incidence of DN = f (Comorbidities, glycemic control, alcohol
- drinking+ physical activity + hypertension+ type of treatment+ WBC count+ RBC count)
- 342 Domain: All type-1 and type-2 DM patients at risk for developing diabetic neuropathy

343 Nomogram and classification and regression tree development

Nomogram, which are reliable prediction tools, with the ability to generate an individual probability of a clinical event by incorporating a number of prognostic determinant variables

346 (56) was developed to predict individual risk of diabetic neuropathy among DM patients at 347 diabetic clinic of university of Gondar comprehensive specialized hospital and Felege Hiwot referral hospital. The total nomogram score were classified as low risk, intermediate and 348 high-risk scores to see size of each category. Classification and Regression Tree (CRT) 349 350 analysis was performed to determine the complex interactions among the most potent 351 candidate predictors in the final reduced model to build the classification trees. Youden-index was used to estimate cut off point for predictive probability of diabetic neuropathy at 352 different threshold. By choosing the cutoff value get from Youden's index the sensitivity, 353 specificity, NPV, PPV and accuracy was calculated and cut off value was selected depend 354 355 availability of resources and aim of implemented program.

356 **Risk prediction model performance**

357 The reduced multivariable model was evaluated by calibration and discrimination (57).

Model discrimination is the model's ability to discriminate between subjects with and 358 without the diabetic neuropathy was estimated through the areas under the ROC curve. The 359 area under the receiver operating characteristic curve (AUC) ranges between 0.5-1. Model 360 calibration is examined the level of agreement between the diabetic neuropathy probabilities 361 estimated by the model versus the observed diabetic neuropathy frequencies through 362 graphical comparison, calibration plot. Good calibration means that the estimated probability 363 of diabetic neuropathy is similar to the observed diabetic neuropathy frequency. Statistically 364 we checked by the Homer and Lemeshow test with a significant P- value implies that the 365 model is not well calibrated as it performs differently for different risk categories. Finally the 366 results were presented using statement, table, figures and reported according to transparent 367 reporting of multivariable prediction model for individual progress or diagnosis 368 (TRPOID)statement(58) 369

370 Internal validation

In risk prediction model, validating the model expected from the researchers in order to apply in clinical practice. In this study by using bootstrapping method internal validation was done to avoid over fitting of the model (57). The first step in bootstrapping method is the model was developed in the full sample. Then multiple random minimum samples (1000) draw from the full sample. The calibration and discrimination of each bootstrap model were compared to the corresponding estimates of the bootstrap models when applied in the

original full sample. These differences were averaged, and provide an indication of theaverage optimism of the bootstrap models.

Decision curve analysis

380 Decision curve analysis was done to evaluate prediction models that is important for medical 381 decision making to overcome the limitations discrimination and calibration(59). It was done 382 graphically for model, treatment for all, and treatment for none. The net benefit of the 383 developed model for carrying out a certain intervention measure in DM patients at risk of 384 developing diabetic neuropathy was done by decision curve plot.

385 Mobile based application of Nomogram

386 Application of the nomogram by mobile based is useful to facilitate limited resources in poor healthcare systems to get evidence based clinical decision making. To make the nomogram 387 accessible to physicians and patients, mobile based application tool were developed for 388 predicting risk of diabetic neuropathy in diabetes mellitus patients. The mobile based tool 389 390 was developed by "sublime text" application with java script and used to calculate the risk of diabetic neuropathy for DM patients without requiring internet service "off line" in clinical 391 setting. Where clinicians or diabetes mellitus patients enter his/her selected clinical and 392 laboratory data then developed mobile based application toll giving alert as low risk or high 393 risks of diabetic neuropathy to keep or improve their health condition. 394

395 **Results**

Socio-demographic and behavioral characteristics of DM patients

A total of 808 diabetes mellitus patients who had follow up visit were included. The mean baseline age of diabetes mellitus patients was 45.6 ± 3.1 years. More than three-fourth 616(76.2%) diabetes mellitus patients were from urban residents (Table-1)

400 Table 1:-Socio-demographic and behavioral predictors of diabetic neuropathy among

diabetes mellitus patients in North West, Ethiopia, 2005-2021 (n=808)

Predictors	Diabetic Ner	uropathy	Frequency	Percentage
	Yes	No		
Sex				
Male	73	327	400	49.5

Female	99	309	408	50.5	
Baseline age					
< 45 years	62	321	383	47.4	
>=45 years	110	315	425	52.6	
Residence					
Rural	26	166	192	23.8	
Urban	146	470	616	76.2	
Alcohol drinking					
Yes	74	98	172	21.3	
No	287	349	636	78.7	
Physical activity					
Yes	311	325	636	78.7	
No	75	97	172	21.3	
Unhealthy diet					
Yes	83	89	172	21.3	
No	321	315	636	78.7	

402

403 Diagnosis and treatment related characteristics of DM patients

More than two-third of patients 545(67.5%) were type-2 DM patients and half of them 405 401(49.6%) diabetes mellitus patients were used oral drugs medication. Nearly half of the 406 diabetes mellitus patients 385(47.6%) had other comorbidities. Majority of diabetes mellitus 407 patients 557(71.4%) had good adherence (Table-2).

Table 2:-Clinical predictors of diabetic neuropathy among diabetes mellitus patients North West, Ethiopia, 2005-2021 (n=808)

Predictors	Diabetic Neuropathy		Frequency	Percentage
	Yes	No		
Type of diabetes mellitus				
Type-1 DM	35	228	263	32.5
Type-2 DM	137	408	545	67.5
Type of treatment for diabetes mellitus				
Insulin only	55	293	348	43.1
Oral drugs only	96	305	401	49.6

Insulin and oral drugs	21	38	59	7.3
Body mass index in kg/m ²				
<18.5	9	28	37	4.6
18.5-24.9	54	191	245	30.3
>=25	109	417	526	65.1
Mean arterial blood pressu	re			
>100 mmHg	62	152	214	26.5
70-100 mmHg	110	484	594	73.5
Other comorbidities				
Yes	50	373	423	52.4
No	122	263	385	47.6
Adherence				
Poor	52	179	231	28.6
Good	120	457	577	71.4
Hypertension				
Yes	99	244	343	42.5
No	73	392	465	57.5
Duration of DM in years				
<6 years	71	257	328	40.6
6-11 years	79	316	395	48.9
>11 years	22	63	85	10.5

410

411

412 Laboratory related characteristics of diabetes mellitus patients

413 The mean value of fasting blood glucose level was 92 ± 15 and the mean total cholesterol

and total triglyceride level had 189.9 ± 58.7 and 170.5 ± 73.7 mg/dl respectively. (Table-3)

415 Table 3:-Laboratory related predictors diabetic neuropathy among diabetes mellitus

416 patients North West, Ethiopia, 2005-2021(n=808)

Predictor	Mean ± SD
Mean fasting blood glucose(mg/dl)	92 ± 15
Hemoglobin(g/dl)	13.9 ± 1.8
Total cholesterol level(mg/dl)	189.9 ± 58.7

Total triglyceride level(mg/dl)	170.5 ± 73.7
Creatinine(mg/dl)	0.9 ± 0.6
White blood cells(Cells/microliter)	$6.9 \pm 2.8 \text{ x}10^3 \text{ cells/mcl}$
Red blood cells(Cells/microliter)	$4.8\pm0.9x10^6~cells/mcl$
Platelets(Cells/microliter)	$233 \pm 74 \times 10^3$ cells/mcl

417 Incidence of diabetic neuropathy

The incidence proportion of diabetic neuropathy was 172 (21.29 %, 95% CI; 18.59, 24.25)

419 Type-2 diabetes mellitus 137(79.65%) had highest incidence of diabetic neuropathy whereas

420 35(20.35%) were found in type-1 diabetes mellitus patients. (Figure-2)

421 Figure 2; Pie chart for the proportion of diabetic neuropathy among diabetes mellitus

422 patients North West, Ethiopia, 2005-2021.

423 **Prediction model development and validation**

424 Selected predictors

- In this risk prediction model socio-demographic, diagnosis and treatment related, laboratory
 and behavioral related predictors were considered for development of prediction model of
 diabetic neuropathy.
- The candidate predictors were selected by least absolute shrinkage and selection operator (LASSO) regression for the development and validation of model for diabetic neuropathy (Table-4). Multi- collinerity test was checked by VIF and unhealthy diet was not included in
- 431 our model due to high VIF (17.8).

432 Table 4:- Optimum shrinkage factor (lambda) and potential predictors identified by

433 lasso regression by 10-fold cross validation selection method for diabetic neuropathy

434 among diabetes mellitus patients North west, Ethiopia 2005-2021.(n=808)

ID	Description	Lambda	No. of non- zero	Out of sample	CV mean
			coefficients	dev. Ratio	deviance
1	First lambda	0.09923	0	0.0023	1.037898
21	Lambda before	0.015437	12	0.0575	0.9759118
*22	selected lambda	0.0140656	13	0.0578	0.0756381
23	Lambda after	0.012816	13	0.0576	0.9757846
27	Last lambda	0.0088336	19	0.0553	0.9782416

Thirteen variables were selected by Lasso regression and included in the multiple logistic regression models (Table-5). Finally, we construct the clinical risk prediction model with eight statistically significant predictors including hypertension, glycemic control (FBG), other comorbidities, Alcohol drinking, physical activity, type of treatment for DM, WBC and RBC count. Goodness of fit test was checked had insignificant p-value 0.3077, best fitted model.

442 Table 5:-Multi variable logistic regression for variables retained in the final reduced

443 model to predict diabetic neuropathy among DM patients Northwest Ethiopia, 2005-

444 **2021.** (n=808)

Predictors	Diab	etic	Multi variable analy	sis	Model reduction
	neurop	athy			
	No	Yes	Beta coefficients	P-value	P- value
			(95 % CI)		
Baseline age in ye	ears				
<45 years	321	62	0		
>=45 years	315	110	0.15(-0.28,0.59)	0.516	
Sex					
Female	309	99	0		
Male	327	73	-0.26(-0.63,0.10)	0.157	
Residence					
Rural	166	26	0		
Urban	470	146	0.28(-0.23,0.79)	0.279	
Type of DM					
Type-1 DM	228	35	0		
Type-2 DM	408	137	0.024(-0.6, 0.7)	0.944	
Mean arterial bloc	od pressu	ure			
70-100 mmHg	484	110	0		
>100 mmHg	152	62	0.15(-0.25,0.56)	0.459	
Type of treatment					
Both insulin and	38	21	0		
oral drug					
Insulin only	305	96	-0.49(-1.32,0.10)	0.05	0.02 *

Oral drugs only	293	55	-0.61(-1.09,0.15)	0.139	
Baseline glycemic	c control				
<130mg/dl	148	25	0		
>=130mg/dl	488	147	0.58(-0.01 ,1.16)	0.04	0.04*
Other comorbiditi	es				
No	373	50	0		
Yes	263	122	1.29(0.85,1.68)	0.000	0.00*
Alcohol drinking					
No	349	287	0		
Yes	98	74	1.13(.015, 2.25)	0.04	0.003*
Physical Activity					
No	97	75	0		
Yes	325	311	-1.79(-2.94,-0.7)	0.002	0.001*
Hypertension					
No	392	73	0		
Yes	244	99	0.412 (0.00 , 0.82	0.04	0.01*
White blood cells/	/microlit	ter			
4500-11000	266	82			
<4500	33	20	-1.14(-2.2, -0.01)	0.04	0.03*
>11000	337	70	0.15(-0.58, 0.89)	0.684	
Red blood cells/m	nicroliter				
4-6 million	270	80	0		
<4 million	34	20	0.90(.056 ,1.74)	0.03	0.03*
>6 million	332	72	-0.24(-0.99 0.52)	0.539	
_cons			-1.96(-2.97,0.94)	0.000	

445

446 Prediction model development using original beta coefficients

By using area under ROC curve the discriminating power of the model was evaluated and individual predictors in the final reduced model had poor performance discriminating the risk of diabetic neuropathy among DM patients starting from 51.1 % to 62 .4% but they had good discriminating ability in combined effect. The predictive performance of model using combination of other comorbidities, glycemic control, physical activity and WBC had 70.0%. The predictive performance powers of each predictor were displayed (supplementary file S-

2). The area under curve (AUC) of the final reduced model using original beta coefficients

454 were 73.49 %(95% CI; 69.3%, 77.6%).(Figure-3, A). The developed model had calibration

test value (p-value=0.451) well calibrated model, the model well represented the data that

456 was agreement between observed and the predicted probability (Figure-3, B)

- 457 Figure 3: The performance of the model using original beta coefficients A) AUC B)
- 458 calibration plot, for prediction of diabetic neuropathy among DM patients North West
- 459 Ethiopia, 2005-2021.
- 460 The probability for risk of diabetic neuropathy using original beta coefficients was
- 461 P(Diabetic-neuropathy)=1/1+exp-(-1.96+0.9*RBC(low)-1.14*WBC(low) +0.4*Hypertension
- 462 (yes)-1.79*Physical activity (yes) +1.13*Alcohol drinking (yes) +1.29*other comorbidities
- 463 (yes) +0.58*Glycemic control (poor)-0.72*type of treatment (insulin only)

464 **Prediction model development using nomogram**

For the sake of simplicity and easy to use in clinical practice the model was developed by 465 nomogram (Logistic regression). All significant regression coefficients in the final reduced 466 467 model were used for model development. The model presented by monogram through eight significant variables that predicts diabetic neuropathy was displayed (Figure-4). From 468 nomogram the possible minimum and maximum score was 0 to 47.2 with different threshold 469 probabilities to develop diabetic neuropathy. The cut off value to nomogram score as the 470 471 probability of 0.24 was 26. Hence, DM patients who had ≤ 26 score from nomogram total score was low risk whereas those who had >=26 score from total score was as high risk to 472 473 develop diabetic neuropathy.

474 Figure 4:- Nomogram for develop and validate risk prediction model for diabetic

- neuropathy among diabetes mellitus patients, northwest Ethiopia, 2005-2021.
- The performance of developed nomogram in predicting diabetic neuropathy was AUC= 73.2 %(95% CI; 69.0%, 77.3%), had good level of accuracy (Figure-5, A) and calibration test (pvalue 0.502), the model was well calibrated model, indicates the observed probability was agreement with expected probability (Figure-5, B).

Figure 5: Performance of model using nomogram A) AUC B) Calibration plot,
prediction for the risk of diabetic neuropathy among DM patients North West Ethiopia
2005-2021.

483 Prediction model development using machine learning by classification and 484 regression tree

485 Besides the model developed by nomogram, it also presented by machine learning algorism 486 with classification and regression tree analysis suitable when continuous and categorical 487 variables used that predict diabetic neuropathy. The prediction rate (accuracy) for diabetic 488 neuropathy in classification and regression tree was 78.7% (Table-6).

489 Table 6:- Prediction rate of diabetic neuropathy among DM patients using machine 490 learning by CRT decision tree in North West Ethiopia, 2005-2021

491

	Cla	ssification	
Observed	Predi		
	No	Yes	Percent Correct
No	636	0	100.0%
Yes	172	0	0.0%
Overall Percentage	100.0%	0.0%	78.7%

492

493

494 From eight significant variables used for nomogram development, the classification and 495 regression tree (CRT) select five most potent predictors includes other comorbidities, glycemic 496 control, physical activity, White blood cells and red blood cells count. Presence of 497 comorbidities was the most important node that predicts diabetic neuropathy, followed by 498 glycemic control and physical activity; low RBC and high WBC count. For instance, from 172 499 having diabetic neuropathy cases, 59(43.1%) had presence other comorbidities and no doing 500 physical activity were develop diabetic neuropathy. In classification and regression tree there 501 were four depths, six terminal nodes used for decisions (Figure-6).

502 Figure 6:-Classification and regression decision tree for prediction of diabetic neuropathy 503 among diabetes mellitus patients North West Ethiopia 2005-2021

504 The performance of the classification and regression decision tree was good accuracy with

505 AUC=70.2 %(95 % CI; 65.8%, 74.6%) (Figure:-7, A) and well calibrated model (p-value -

506 0.412) (Figure:-7, B), which means the predicting and observed probability was the same

507 Figure 7:-The Performance of the model using decision tree A) AUC B) calibration plot

508 to prediction of the risk for diabetic neuropathy among DM patients North West

509 Ethiopia 2022.

510 Internal validation

In order to checking over fitting and bias of the developed model using nomogram and decision tree, bootstrapping technique were used for internal validation. The area under ROC curve was assessed based on the bootstrap dataset coefficients. The developed nomogram was internally validated had AUC; 71.7(95% CI; 67.3 %, 76.0%) (Figure-8, A) and well

- calibration model (p-value- 0.945)(Figure-8, B)
- 516 After internal validation the discriminating performance of nomogram was comparable with
- 517 less optimism coefficients found to be 0.015, which indicates less likely over fitting model
- and bias. The average calculated value of optimism to the performance model was 0.0075.

519 Figure 8: The performance of the model using nomogram after bootstrapping A) Area

520 under the curve (AUC) B) calibration plot, for the probability of the risk of diabetic

neuropathy among DM patients North West Ethiopia, 2005-2021.

522 The performance of the classification and regression decision tree after bootstrapping was the

same as the developed CRT decision tree ,good accuracy with AUC=70.2 %(95 % CI;

524 65.8%, 74.6%) (Figure:-9 A) and well calibrated model (p-value:-0.389) (Figure:-9 B). The 525 optimism coefficient was 0.000.

Figure 9:-The performance of the model using classification and regression decision tree after bootstrapping A) AUC B) Calibration plot to predict diabetic neuropathy among DM patients northwest Ethiopia 2022.

In both nomogram and classification and regression tree (CRT) the discrimination and calibration performance power were comparable, good accuracy so that, they were used to predict the risk of diabetic neuropathy among DM patients (Figure-10)

Figure 10: Comparison of nomogram and decision tree for prediction of diabetic
neuropathy among DM patients North West Ethiopia 2005-2021.

534 Cutoff point for probability of diabetic neuropathy by nomogram and 535 CRT

Using the nomogram, optimal cutoff point for predicted probability for risk of diabetic neuropathy by using Youden's index(J) was 0.2447 and the sensitivity, specificity, positive predictive value and negative predictive value was 65.2%(95% CI; 58;0%, 72.2%),

539 71.7%(95% CI; 68.0%, 75.2%), 38.4%(95% CI; 32.7 %, 44.2%), 88.4% (95% CI; (85.3%,

- 540 91.0%) respectively.(Table-7)
- 541 Table 7:-Sensitivity, Specificity, PPV, NPV, LR+, LR- and Accuracy of the nomogram
- 542 at different cut-off points for prediction of diabetic neuropathy among DM patients
- 543 North West Ethiopia 2005-2021.

Cutoff	Sensitivity	Specificity	Accuracy	PPV	NPV	LR+	LR_
>=0.1	72.1%	63.5	65.4%	35.3%	90.4%	1.9	0.4
>=0.2	70.4%	66.4%	67.2%	36.1%	89.2	2.1	0.4
>=0.24	65.2%	71.7%	70.3%	38.4%	88.4	2.3	0.4
>=0.3	54.7%	78.6%	73.5%	41.0%	86.5%	2.5	0.5
>=0.4	34.3 %	88.4%	77.0%	44.4%	83.3%	2.9	0.7

544

In classification and regression tree(CRT) using optimal cutoff point for predicting the probability risk of diabetic neuropathy by using Youden's index was 0.1847 and the sensitivity, specificity, positive predictive value and negative predictive value was 72.09 (95% CI; 64.8%, 78.6%), 57.7%(95% CI; 53.8%, 61.6%), 31.5%(95% CI; 27.0 %, 36.4%), 88.4% (95% CI; (84.9%, 91.3%) respectively.

550 **Risk classification for diabetic neuropathy using nomogram**

For easily practical utility we developed nomogram by using regression coefficients in the final reduced model. The proportion of diabetes mellitus patients to risk of diabetic neuropathy at low risk was 516(63.8%), intermediate risk 282(34.90%) and high risk group 10(1.24%). When the risk classified as two categories the proportions of DM patients for risk

- of diabetic neuropathy at low risk was 516(63.86%) and high risk 292(36.14%).(Table-8)
- 556 Table 8: Risk classification for predicting diabetic neuropathy among DM patients

```
557 using nomogram, Northwest Ethiopia, 2005-2021 (n=808)
```

Risk categories'	Total number of DM patients	Incidence of diabetic neuropathy		
Low risk(<0.2)	516(63.86%)	60(7.4%)		
Intermediate risk(0.2-0.6)	282(34.90)	107(13.3%)		
High risk(>0.6)	10(1.24%)	5 (0.6%)		
Total	808(100%)	172(21.3%)		

In classification and regression tree (CRT), the proportion diabetes mellitus patients to the risk of diabetic neuropathy at low risk was 150(18.56%), intermediate risk 636(78.72) and high risk 22(2.72%).

562 **Decision Curve analysis**

Besides model performance assessed by AUC, calibration plot, sensitivity, specificity and accuracy, clinical and public health utility of the model was also assessed by decision curve analysis. The developed model using nomogram and classification and regression tree (thick red line} had highest net benefit from threshold probabilities greater than 0.1(10%) compared treatments none (thick black line), had high cost benefit ratio. The model has no or similar net benefit to treatment all (thin black line) regardless of their risk across thresholds below 0.1 (10%).(Figure-11, A, B)

570

571 Figure 11:-Decision curve plot A) Nomogram B) Decision tree ,showing the net benefit 572 of the developed model for carrying out a certain intervention measure in DM patients

573 at risk of diabetic neuropathy Northwest Ethiopia, 2005-2021

574 Mobile-based application of nomogram

To make the nomogram accessible to physicians and patients, mobile based application tool 575 576 were developed for predicting the risk of diabetic neuropathy among diabetes mellitus patients by using "sublime text "application with java script. Where physicians' or diabetes 577 mellitus patients enter their selected clinical and laboratory data to the developed mobile 578 based tool, then the tool was giving alert as cutoff value 26 get from nomogram, weather they 579 are at low risk (<26) or high risk (>=26) of diabetic neuropathy by calculating cumulating 580 score in order to keep or improve their health condition. In Figure:-15 when we enter data to 581 the tool had score 21.2 582

Figure 12:-Mobile based application outputs for predicting risk of diabetic neuropathy among DM patients Northwest Ethiopia 2005-2021.

585 **Discussion**

This risk prediction model used a multicenter retrospective follow up study to develop a practical tool for prediction of diabetic neuropathy among both type-1 and type-2 DM patients. Our study established a diabetic neuropathy risk prediction model using combined

set predictors to be used in the primary care settings, by developing nomogram and decision
tree, aid in public health and clinical decision making for clinicians and to patients.

There were challenges to diagnose diabetic neuropathy, which needs electro physical and autonomic tests by mono filaments, is not available in low level health care system (60, 61) Hence, predicting the risk of diabetic neuropathy in diabetes mellitus patients using easily measurable predictors were essential to take appropriate measures accordingly.

595 The study finding showed that the incidence proportion of diabetic neuropathy was 21.29

596 %(95%CI; 18.59, 24.25), which is consistent with SRMA study in North Africa, 21.9% (18),

597 Ethiopia, 22% (50), Qatar 23.0%(62) but lower than Tikur Anbesa and St. Paulous 598 hospital,48.2% (20), SRMA in Africa 46% (15), Srilanka 28.8% (14).

These disparities might be number of participates involved with sample size difference, in case small sample size in this study(63),difference way of life style (64) and different level of health care system used for diagnosis. For instance, monofilament examination was not performed in our study area, results asymptomatic patients may not detect.

The model was developed by reducing twenty-two candidate predictors to thirteen potential predictors, which were passed to multivariable analysis. The model comprised eight variables identified as independent predictors of diabetic neuropath including glycemic control (FBG), other comorbidities, alcohol drinking, Hypertension, type of treatment for DM, physical activity, WBC and RBC count. This result is supported by previous studies conducted (65), (66), (37), (42), (47),(67).

The prediction model developed from eight predictors and nomogram was developed found to have discrimination accuracy of AUC; 73.2% This result showed that a good accuracy discrimination power according to diagnostic accuracy classification criteria(68). The model calibration assessed by calibration plot and Hosmer and Lemeshow test had p-value; 0.502, which had good agreement between observed and expected probability.

The predictive role of each predictors was assessed for the identification of individuals at greater risk of diabetic neuropathy and its capacity of score from nomogram for glycemic control (poor), physical activity (no), other comorbidities (yes), alcohol drinking (yes), use combined insulin and oral drugs, hypertension (yes), WBC (high) and RBC (low) was 2.6, 10, 7, 6.4, 4, 2.6, 7.8 and 6.8 respectively.

The model was internally validated using the bootstrapping method of 1000 repetitions with replacement. The discriminating performance of the model after internal validation had also good discrimination power of AUC ;71.7% with well calibrated model (p value = 0.945). The

optimism coefficient was found to be 0.015(1.5%), ensures that the model is less likely over
fitting and less sample dependent, can easily and accurately individualized prediction of the
risk of diabetic neuropathy.

The performance of our model was found to be consistent with other prediction models 625 626 developed to predict diabetic neuropathy among DM patients, using hypertension, age, heart 627 rate and BMI as predictors, AUC; 71% in china(69) using hypertension, comorbidities, gender, age, obesity, abnormal triglycerides as predictors, AUC; 75% in china (70), but better 628 than a study using glomerular filtration rate, glibenclamide and creatinine as predictors 629 630 AUC=66.05% in Mexico (71), using age, FBG, PBG, HbA1c, LDL, HDL and BMI as predictors AUC; 55.6% in china(72), using FBG, BMI, age as predictors AUC; 63.50 in 631 Korea (73). This might be due to difference in study participants involved through socio-632 633 demographic characteristics, difference number of predictors used in the model development (74). The model calibration based on Hosmer and Lemshow test P-value; 0.945, is consistent 634 another study 0.52 in china (72), indicates well calibrated model. 635

However, the discriminative performance of the model was lower than a study done in Italy
using type of DM, smoke, BMI and HbA1c as predictors AUC ; 76.9%(75) and AUC; 85.9%
in china(40). This might sample size variation, use variety of validation techniques, the lower
number of predictors incorporated in case of our study compared to others, use machine
learning algorism, to select the most potent predictors increases the power of the study (74).

In our nomogram prediction score, using 0.24 as cutoff point has an acceptable level of the sensitivity; specificity was 65.2%, 71.2%, respectively. Using 0.18 as cut off point in classification and regression tree (CRT) had also acceptable level of sensitivity; specificity was 72.09% and 57.7% respectively. Thus it was better to identify diabetic neuropathy cases and possible to shift the cutoff point to increase either of the accuracy measures depending on the aim of program and availability of resources.

The benefit that the developed nomogram and decision tree would add to clinical practice was also presented in the form of a decision curve analysis. In our study the decision curve analysis showed that there was high net benefit than using treat all or treat none strategies when the threshold probability of the patient greater than 0.1(10%) in both nomogram and classification and regression tree(CRT). However, the model is not useful for threshold probabilities below 10%. Thus, threshold probabilities are the most important components of the decision curve analysis depending on which a clinician can decide on whether to use the

model or not when there is a need to carry out an intervention for patients at risk of diabetic neuropathy.

Although the autonomic tests by monofilament examination and nerve conduction studies gives better diagnosis of diabetic neuropathy(76).However, prediction of diabetic neuropathy among type-1 and type-2 DM patients using clinical and behavioral characteristics of alone enabled to identify low and high risk diabetes mellitus patients.

This prediction model is not a replacement of electro physical diagnosis and monofilament examination of diabetes mellitus patients to diagnose diabetic neuropathy (77); however, it will be as screening tool in resource poor settings for further diagnostic workup and management options. Besides the nomogram and decision tree is easier to use in routine clinical and public health practice than regression models and has comparable discrimination and calibration.

This study has following strengths. Firstly, it was conducted multicenter study and mobile 666 based application toll was developed for easily applicability. Secondly, the model was 667 internally validated using bootstrapping technique, resulted small optimism coefficient, 668 indicating our model is less likely over fitted model, can easily predict the risk of diabetic 669 neuropathy. Thirdly, this prediction model is constructed from easily obtainable clinical and 670 behavioral predictors that make it applicable in primary care settings. Finally the model was 671 also developed by classification and regression tree analysis to show the interaction effect of 672 each predictor to the risk of diabetic neuropathy. 673

However, the findings from this study should be interpreted with the perspective of the 674 following limitations. Even if multicenter studies, the model did not validate in separate 675 datasets so that it needs external validation before using it in another context. In addition 676 most diabetic neuropathy patient was asymptomatic may missed cases, who had no sign and 677 symptoms. The study had many missing predictors due to retrospective study design. 678 Generally the model will provide its maximum benefit in clinical practice provided that all 679 680 the required predictor information is collected and developing mobile based application makes it the nomogram easily applicable for clinicians and to patients. 681

682 Conclusion and recommendation

The model was developed from precisely measured, clinical and behavioral predictors found
in primary health care setting includes glycemic control(FBG), hypertension, physical
activity, other comorbidities, alcohol drinking, type of treatment for DM, WBC and RBC

686 count. The model was presented by nomogram and decision tree with having good discriminating performance power and well calibrated. It was internally validated by 687 bootstrapping techniques with small optimum coefficients, less likely of over fitting of the 688 model. The nomogram was better than decision tree, helps us to do a risk stratification of 689 690 diabetes mellitus patients and to identify those at higher risk of having diabetic neuropathy. 691 Subsequently, high-risk groups can be linked to a center, which is equipped with electro physical diagnosis and monofilament examination centers for further assessment and better 692 693 management. The nomogram and decision tree had added net benefit in clinical practice as it 694 was assured by decision curve analysis across different threshold probabilities. To make easily accessible and applicable of nomogram for clinicians and to patients, mobile based 695 application tool (off line) were developed, that works for both type-1 and Type-2 DM 696 697 patients to calculate their risk in order to take appropriate intervention measures timely.

Based on study findings, we recommend that for health professionals, who are providing 698 health care services at diabetes mellitus chronic follow up clinic, use the nomogram 699 developed by mobile based application tool to identify high risk of diabetic neuropathy 700 patients for early management and treatment. Additionally Patients use this developed mobile 701 based application tool for their informed choice of treatment by calculating their 702 703 individualized risk either to keep or improve their health condition. Finally for future researchers improve the model by adding additional predictors like HbA1c, family history of 704 DM and smoking through prospective study design and using monofilament examination by 705 detect enough number of events. Besides, validate externally by using independent sample 706 707 datasets to be applicable in all health institution.

708 Abbreviations

AUC; Area under the Curve BMI; Body Mass Index CI; Confidence Interval

710 CRT; Classification and Regression Tree DBP; Diastolic Blood Pressure DCA; Decision

711 Curve Analysis DM; Diabetes Mellitus DPN; Diabetic Peripheral Neuropathy

FBG; Fasting Blood Glucose HDL; High Density Lip-Protein HbA1c; Glycated Hemoglobin

A1 c ICT; Information Communication Technology IDF; International Diabetes Federation

714 IQR ; Inter Quartile Range LASSO; Least Absolute Shrinkage and Selection Operator LDL;

Low Density Lip-Protein LR+; Log Likelihood Ratio Positive LR_; Log Likelihood Ratio

716 Negative MNSI ; Michigan Neuropathy Screening Instrument NPV; Negative Predictive

717 Value PBG; Post Bradial Glucose PPV; Positive Predictive Value RBC; Red Blood Cells

718 ROC; Receiver Operating Characteristics SBP; Systolic Blood Pressure SRMA ; Systematic

- 719 Review and Meta-Analysis T1DM; Type-1 Diabetes Mellitus T2DM;Type-2 Diabetes
- 720 Mellitus TC; Total Cholesterol TG; Total Triglyceride UOG; University of Gondar WBC;
- 721 White Blood Cells
- 722 **Declarations**

723 Ethics approval and consent to participate

- The study use ethical clearance from university of Gondar for the collection of information
- 725 from subjects (supplementary file-S3)

726 Availability of data and materials

727 Data is available on the manuscript and as supplementary files.

728 **Competing Interests**

- 729 The authors declare that they have no conflict of interest.
- 730 Funding
- Funding was obtained from Mizan Aman college of health science, Mizan-Aman, Ethiopia
- 732 (25,000 Ethiopian Birr)

733 Author's Contributions

734 Conceptualization: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke

Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu BekeleGebi

737 Data curation: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke

Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie ,Tsion Mulat Tebeje, Nebiyu BekeleGebi

740 Formal analysis: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke

- Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele
- 742 Gebi

743	Investigation: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke Alem,
744	Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi
745	Methodology: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke
746	Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele
747	Gebi
748	Software; Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke Alem,
749	Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi
750	Validation: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke Alem,
751	Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi
752	Visualization: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke
753	Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele
754	Gebi
755	Writing original draft: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw
756	Zeleke Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu
757	Bekele Gebi
758	Writing - review & editing: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche,
759	Adugnaw Zeleke Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje,
760	Nebiyu Bekele Gebi
761	All authors read and approved the final manuscript.

762 Acknowledgments

We greatly acknowledge Mizan Aman College of health sciences for sponsorship anduniversity of Gondar

765 Supplementary file

- 766 S1:- Missing variables and its percentage for prediction of diabetic neuropathy among
- 767 DM patients Northwest Ethiopia, 2005-2021.

768 S2: - Predictive performance of for individual and combined predictors by AUC value

769 for prediction of diabetic neuropathy among DM patients North West Ethiopia 2005-

2021.

771 S3:-Ethical Clearance letter obtained from university of Gondar

772

773 **References**

1. Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nature medicine. 2017;23(7):804-14.

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes
mellitus and its complications. Nature Reviews Endocrinology. 2018;14(2):88-98.

3. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF
Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021
and projections for 2045. Diabetes research and clinical practice. 2022;183:109119.

4. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et
al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for
2045. Diabetes Res Clin Pract. 2018;138:271-81.

Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes:
a disease with increasing heterogeneity. Lancet (London, England). 2014;383(9922):108494.

6. Cho N, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A, et al. IDF
Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.
Diabetes research and clinical practice. 2018;138:271-81.

790 7. Association AD. Standards of medical care in diabetes—2016 abridged for primary
791 care providers. Clinical diabetes: a publication of the American Diabetes Association.
792 2016;34(1):3.

8. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy:
mechanisms to management. Pharmacology & therapeutics. 2008;120(1):1-34.

9. Rojas-Carranza CA, Bustos-Cruz RH, Pino-Pinzon CJ, Ariza-Marquez YV, GomezBello RM, Canadas-Garre M. Diabetes-Related Neurological Implications and
Pharmacogenomics. Current pharmaceutical design. 2018;24(15):1695-710.

10. Said G. Diabetic neuropathy. Handbook of clinical neurology. 2013;115:579-89.

11. Li L, Chen J, Wang J, Cai D. Prevalence and risk factors of diabetic peripheral
neuropathy in type 2 diabetes mellitus patients with overweight/obese in Guangdong
province, China. Primary care diabetes. 2015;9(3):191-5.

Pfannkuche A, Alhajjar A, Ming A, Walter I, Piehler C, Mertens PR. Prevalence and
risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative
"diabetes and nerves". Endocrine and Metabolic Science. 2020;1(1):100053.

Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A. Prevalence
and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus
in a tertiary care setting. Journal of diabetes investigation. 2014;5(6):714-21.

Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MHR,
Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a
developing country. Diabetology & Metabolic Syndrome. 2012;4(1):21.

811 15. Shiferaw WS, Akalu TY, Work Y, Aynalem YA. Prevalence of diabetic peripheral
812 neuropathy in Africa: a systematic review and meta-analysis. BMC endocrine disorders.
813 2020;20(1):49.

814 16. Jacovides A, Bogoshi M, Distiller LA, Mahgoub EY, Omar MK, Tarek IA, et al. An
815 epidemiological study to assess the prevalence of diabetic peripheral neuropathic pain among
816 adults with diabetes attending private and institutional outpatient clinics in South Africa.
817 Journal of International Medical Research. 2014;42(4):1018-28.

818 17. Seid MA, Akalu Y, Gela YY, Belsti Y, Diress M, Fekadu SA, et al. Microvascular
819 complications and its predictors among type 2 diabetes mellitus patients at Dessie town
820 hospitals, Ethiopia. Diabetology & Metabolic Syndrome. 2021;13(1):1-8.

18. Bos M, Agyemang C. Prevalence and complications of diabetes mellitus in Northern
Africa, a systematic review. BMC public health. 2013;13(1):1-7.

- 19. Jember G, Melsew YA, Fisseha B, Sany K, Gelaw AY, Janakiraman B. Peripheral
 Sensory Neuropathy and associated factors among adult diabetes mellitus patients in Bahr
 Dar, Ethiopia. Journal of diabetes and metabolic disorders. 2017;16:16.
- 20. Jarso G, Ahmed A, Feleke Y. The prevalence, clinical features and management of
 periphral neuropathy among diabetic patients in Tikur Anbessa and St. Paul's Specialized
 University Hospitals, Addis Ababa, Ethiopia. Ethiopian medical journal. 2011;49(4):299311.
- 830 21. Selvarajah D, Kar D, Khunti K, Davies M, Scott A, Walker J. Diabetic peripheral
 831 neuropathy: Advances in diagnosis and strategies for screening and early intervention. Lancet
 832 Diabetes Endocrinol [Internet]. 2019; 7 (12): 938–48.
- 833 22. (FMOH) FMoH. National Strategic Action Plan (Nsap) for Prevention & Control of
 834 Non-Communicable Diseases in Ethiopia. 2016.
- 835 23. Smith BH, Hébert HL, Veluchamy A. Neuropathic pain in the community:
 836 prevalence, impact, and risk factors. Pain. 2020;161 Suppl 1:S127-s37.
- 837 24. Marshall A, Alam U, Themistocleous A, Calcutt N, Marshall A. Novel and Emerging
 838 Electrophysiological Biomarkers of Diabetic Neuropathy and Painful Diabetic Neuropathy.
 839 Clinical therapeutics. 2021;43(9):1441-56.
- Kent P, Cancelliere C, Boyle E, Cassidy JD, Kongsted A. A conceptual framework
 for prognostic research. BMC Med Res Methodol. 2020;20(1):172.
- Ambizas EM, Maniara B. Diabetic Peripheral Neuropathy How Can We Help Our
 Patients? : JOBSON PUBLISHING LLC 100 AVE OF THE AMERICAS, NEW YORK, NY
 10013-1678 USA; 2016. p. 8-14.
- Yang Z, Zhang Y, Chen R, Huang Y, Ji L, Sun F, et al. Simple tests to screen for
 diabetic peripheral neuropathy: Cochrane Database Syst Rev. 2018 Jul
 30;2018(7):CD010975. doi: 10.1002/14651858.CD010975.pub2. eCollection 2018 Jul.

28. Lu Y, Xing P, Cai X, Luo D, Li R, Lloyd C, et al. Prevalence and Risk Factors for
Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of
the INTERPRET-DD Study. Frontiers in Public Health. 2020;8.

- 851 29. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and
 852 prognostic research: what, why, and how? Bmj. 2009;338.
- 853 30. Chicharro-Luna E, Pomares-Gómez FJ, Ortega-Ávila AB, Coheña-Jiménez M, Gijon854 Nogueron G. Variability in the clinical diagnosis of diabetic peripheral neuropathy. Primary
 855 care diabetes. 2020;14(1):53-60.
- 856 31. Coppini DV. Diabetic neuropathy: are we still barking up the wrong tree and is857 change finally in sight? Diabetologia. 2020;63(9):1949-50.
- 858 32. Mendoza-Romo MA, Ramírez-Arriola MC, Velasco-Chávez JF, Nieva-de Jesús RN,
 859 Rodríguez-Pérez CV, Valdez-Jiménez LA. [Sensitivity and specificity of a utility model of

860 the detection of diabetic neuropathy]. Revista medica del Instituto Mexicano del Seguro Social. 2013;51(1):34-41. 861 33. Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K, et al. 862 Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in 863 the Middle East region. The Journal of international medical research. 2011;39(2):366-77. 864 865 34. Chicharro-Luna E, Pomares-Gómez FJ. Predictive model to identify the risk of losing protective sensibility of the foot in patients with diabetes mellitus. 2020;17(1):220-7. 866 Papanas N, Ziegler D. Polyneuropathy in impaired glucose tolerance: is postprandial 35. 867 hyperglycemia the main culprit? A mini-review. Gerontology. 2013;59(3):193-8. 868 Xiao M-X, Lu C-H, Ta N, Wei H-C, Haryadi B, Wu H-T. Machine learning 869 36. prediction of future peripheral neuropathy in type 2 diabetics with percussion entropy and 870 871 body mass indices. Biocybernetics and Biomedical Engineering, 2021;41(3):1140-9. Said G. Diabetic neuropathy. Handbook of clinical neurology. 2013;115:579-89. 872 37. 38. Wolde HF, Atsedeweyen A, Jember A, Awoke T, Mequanent M, Tsegaye AT, et al. 873 874 Predictors of vascular complications among type 2 diabetes mellitus patients at University of Gondar Referral Hospital: a retrospective follow-up study. BMC Endocrine Disorders. 875 2018;18(1):52. 876 877 39. Gebabo TF, Zewdie TH, Shagaro SS, Haile F. Determinants of peripheral neuropathy among diabetic patients under follow-up in chronic care clinics of public hospitals at Gamo 878 and Gofa zones, southern Ethiopia. PloS one. 2021;16(2):e0246722. 879 880 40. Fan Y, Long E, Cai L, Cao Q, Wu X, Tong R. Machine Learning Approaches to Predict Risks of Diabetic Complications and Poor Glycemic Control in Nonadherent Type 2 881 Diabetes. Frontiers in pharmacology. 2021;12:665951. 882 41. Wang N, Guo C, Han P, Li T. Glycated albumin indicates peripheral diabetic 883 neuropathy. Acta diabetologica. 2016;53(6):973-9. 884 42. Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus 885 complications. Hypertension Research. 2018;41(3):147-56. 886 Cai Z, Yang Y, Zhang J. A systematic review and meta-analysis of the serum lipid 887 43. profile in prediction of diabetic neuropathy. Sci Rep. 2021;11(1):499. 888 Tabatabaei-Malazy O, Mohajeri-Tehrani M, Madani S, Heshmat R, Larijani B. The 889 44. 890 prevalence of diabetic peripheral neuropathy and related factors. Iranian journal of public health. 2011;40(3):55. 891 892 Wu B, Niu Z, Hu F. Study on Risk Factors of Peripheral Neuropathy in Type 2 45. 893 Diabetes Mellitus and Establishment of Prediction Model. Diabetes Metab J. 2021;45(4):526-38. 894 46. Abougalambou SS, Abougalambou AS. Explorative study on diabetes neuropathy 895 896 among type II diabetic patients in Universiti Sains Malaysia Hospital. Diabetes & metabolic 897 syndrome. 2012;6(3):167-72. Nalluri L, Mannam M, Vemireddy N, Akula N, Pothuraju M, Pinnika D, et al. 898 47. 899 Assessment of drug utilization pattern and risk factors for the development of diabetic neuropathy among type 2 diabetic patients in a south Indian hospital: A cross-sectional 900 observational study. Journal of Applied Pharmaceutical Science. 2019;9(12):069-77. 901 902 48. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nature reviews Disease primers. 2019;5(1):1-18. 903 49. Steverberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. 904 Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS medicine. 905 2013;10(2):e1001381. 906 Tadesse DB, Gebrewahd GT, Hailay A, Aberhe W, Mebrahtom G, Zereabruk K, et al. 907 50. 908 Diabetic peripheral neuropathy in Ethiopia: a systematic review and meta-analysis. Journal of 909 Diabetes Research. 2021;2021.

910 51. Gill G, Mbanya J-C, Ramaiya K, Tesfaye S. A sub-Saharan African perspective of diabetes. Diabetologia. 2009;52(1):8-16. 911 Assessment G. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. 912 52. Diabetes Care. 2022;45:S83. 913 914 53. Carroll MD, Kit BK, Lacher DA. Total and high-density lipoprotein cholesterol in 915 adults; national health and nutrition examination survey, 2009-2010. 2012. 916 54. Bain BJ. Blood cells: a practical guide: John Wiley & Sons; 2021. 55. Kent S, Fusco F, Gray A, Jebb SA, Cairns BJ, Mihaylova B. Body mass index and 917 918 healthcare costs: a systematic literature review of individual participant data studies. Obesity 919 Reviews. 2017;18(8):869-79. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more 920 56. 921 than meets the eye. The Lancet Oncology. 2015;16(4):e173-80. Ge X, Pan SM, Zeng F, Tang ZH, Wang YW. A simple Chinese risk score model for 922 57. 923 screening cardiovascular autonomic neuropathy. PloS one. 2014;9(3):e89623. 924 58. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a 925 multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Journal of British Surgery. 2015;102(3):148-58. 926 927 59. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagnostic and prognostic research. 2019;3:18. 928 929 Jensen TS, Karlsson P, Gylfadottir SS, Andersen ST, Bennett DL, Tankisi H, et al. 60. 930 Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain. 2021;144(6):1632-45. 931 932 Malik RA, Andag-Silva A, Dejthevaporn C, Hakim M, Koh JS, Pinzon R, et al. 61. 933 Diagnosing peripheral neuropathy in South-East Asia: a focus on diabetic neuropathy. Journal of Diabetes Investigation. 2020;11(5):1097-103. 934 Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-muhannadi H, et al. 62. 935 Prevalence and management of diabetic neuropathy in secondary care in Oatar. 936 Diabetes/Metabolism Research and Reviews. 2020;36(4):e3286. 937 Heckmann T, Gegg K, Gegg A, Becht M. Sample size matters: investigating the 938 63. effect of sample size on a logistic regression susceptibility model for debris flows. Natural 939 940 Hazards and Earth System Sciences. 2014;14(2):259-78. Bando H. Significant Neurological Study for Lifestyle Related Diseases Worldwide 941 64. From Now. Journal of Health Care and Research. 2020;1(2):50-4. 942 943 65. Fasil A, Biadgo B, Abebe M. Glycemic control and diabetes complications among diabetes mellitus patients attending at University of Gondar Hospital, Northwest Ethiopia. 944 Diabetes, metabolic syndrome and obesity: targets and therapy. 2019;12:75. 945 946 66. YimamAhmed M, Ejigu SH, Zeleke AZ, Hassen MY, Glycemic control, diabetes 947 complications and their determinants among ambulatory diabetes mellitus patients in 948 southwest ethiopia: A prospective cross-sectional study. Diabetes, Metabolic Syndrome and 949 Obesity: Targets and Therapy. 2020;13:1089. Huang L, Shen X, Huang L, Yan S, Wu P. Identification of independent risk factors 950 67. for diabetic neuropathy progression in patients with type 2 diabetes mellitus. Journal of 951 952 International Medical Research. 2021;49(9):03000605211044366. Simundić A-M. Measures of diagnostic accuracy: basic definitions. Ejifcc. 953 68. 2009;19(4):203. 954 69. Ge X, Pan S-M, Zeng F, Tang Z-H, Wang Y-W. A simple Chinese risk score model 955 for screening cardiovascular autonomic neuropathy. PloS one. 2014;9(3):e89623. 956 957 70. Liao L-N, Li T-C, Li C-I, Liu C-S, Lin W-Y, Lin C-H, et al. Genetic risk score for 958 risk prediction of diabetic nephropathy in Han Chinese type 2 diabetes patients. Scientific 959 reports. 2019;9(1):1-9.

960 71. Maeda-Gutiérrez V, Galván-Tejada CE, Cruz M, Valladares-Salgado A, Galván961 Tejada JI, Gamboa-Rosales H, et al., editors. Distal symmetric polyneuropathy identification
962 in type 2 diabetes subjects: A random forest approach. Healthcare; 2021: MDPI.

963 72. Wu B, Niu Z, Hu F. Study on Risk Factors of Peripheral Neuropathy in Type 2
964 Diabetes Mellitus and Establishment of Prediction Model. Diabetes & metabolism journal.
965 2021;45(4):526-38.

966 73. Shin DY, Lee B, Yoo WS, Park JW, Hyun JK. Prediction of Diabetic Sensorimotor
967 Polyneuropathy Using Machine Learning Techniques. Journal of Clinical Medicine.
968 2021;10(19):4576.

969 74. Muschelli J. ROC and AUC with a binary predictor: a potentially misleading metric.
970 Journal of classification. 2020;37(3):696-708.

75. Dagliati A, Marini S, Sacchi L, Cogni G, Teliti M, Tibollo V, et al. Machine learning
methods to predict diabetes complications. Journal of diabetes science and technology.
2018;12(2):295-302.

974 76. Marshall A, Alam U, Themistocleous A, Calcutt N, Marshall A. Novel and emerging
975 electrophysiological biomarkers of diabetic neuropathy and painful diabetic neuropathy.
976 Clinical therapeutics. 2021;43(9):1441-56.

977 77. Petropoulos IN, Ponirakis G, Khan A, Almuhannadi H, Gad H, Malik RA.
978 Diagnosing diabetic neuropathy: something old, something new. Diabetes & metabolism
979 journal. 2018;42(4):255.

980

981



Figure 1:-Flowchart of participant selection for the development of nomogram for prediction of

diabetic neuropathy among DM patients in selected referral hospitals, Amhara regional state, North West Ethiopia, 2005-2021.





Figure 2; Pie chart for the proportion of diabetic neuropathy among diabetes mellitus patients North West, Ethiopia, 2005-2021.





Figure 3: The performance of the model using original beta coefficients A) AUC B) calibration plot, for prediction of diabetic neuropathy among DM patients North West Ethiopia, 2005-2021.





Figure 4:- Nomogram for develop and validate risk prediction model for diabetic neuropathy among diabetes mellitus patients, northwest Ethiopia, 2005-2021.





medRxiv preprint doi: https://doi.org/10.1101/2022.10.10.22280924; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Figure 5: Performance of model using nomogram A) AUC B) Calibration plot, prediction for the risk of diabetic neuropathy among DM patients North West Ethiopia 2005-2021.





Figure 6:-Classification and regression decision tree for prediction of diabetic neuropathy among diabetes mellitus patients North West Ethiopia 2005-2021





Figure 7:-The Performance of the model using decision tree A) AUC B) calibration plot to prediction of the risk for diabetic neuropathy among DM patients North West Ethiopia 2022.





Figure 8: The performance of the model using nomogram after bootstrapping A) Area under the curve (AUC) B) calibration plot, for the probability of the risk of diabetic neuropathy among DM patients North West Ethiopia, 2005-2021.





Figure 10: Comparison of nomogram and decision tree for prediction of diabetic neuropathy among DM patients North West Ethiopia 2005-2021.





Figure 11:-Decision curve plot A) Nomogram B) Decision tree , showing the net benefit of the developed model for carrying out a certain intervention measure in DM patients at risk of

developed model for carrying out a certain intervention measure in DM patients at risk of diabetic neuropathy Northwest Ethiopia, 2005-2021

Figure

Diabetic Neuropathy Risk Prediction Calculator
Glycemic Control <130 mg/dl v 0
Other comorbidities Yes V 7
Alcohol Drinking Yes V 6.4
medRxiv preprint doi: https://doi.org/10.1101/2022.10.10.22280924; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Physical Activity Yes V 0
WBC >=11000 cells/mcl V 7.8
RBC >=4 million cells/mcl ~ 0
Calculate Cummulative Score 21.2
Clear

Figure 12:-Mobile based application outputs for predicting risk of diabetic neuropathy among DM patients Northwest Ethiopia 2005-2021.





Figure 9:-The performance of the model using classification and regression decision tree after bootstrapping A) AUC B) Calibration plot to predict diabetic neuropathy among DM patients

northwest Ethiopia 2022.

